Exelixis, Inc.

Petrolite Corporation

Nexmed (holdings) Incorporated

Exelixis Patent Company LLC

Baker Hughes Corporation

Bj Services Company

Other

Tanabe Seiyaku Company, Limited

Madcap Software, Inc.

X-ceptor Therapeutics, Inc.

Qualcomm Incorporated

Bristol-myers Squibb Compnay

Baker Hughes, a Ge Compnay, LLC

Daiichi Sankyo Company, Limited

Ferring International Center Sa.

Richard Martin

Brenton Todd Flatt

Raju Mohan

Tie-Lin Wang

Xiao-Hui Gu

Brett Bradley Busch

Bassam Damaj

Michael Charles Nyman

William C Stevens, Jr

Edwin J Schweiger

Bernardus A Oude Alink

Daniel W Frank

Jeffrey Dean Kahl

Yinong Xie

Jason H Wu

Venkataiah Bollu

Ronald Griffith

Jo Ann McMahon

Shao Po Lu

Brett Murphy

Matthew A Williams

John M Nuss

Yong Wang

Kazumasa Aoki

Timothy Patrick Forsyth

Benjamin T Outlaw

Lynne Canne Bannen

Marek K Pakulski

Larry Wayne Mann

Morrison B Mac

Jeff Z Chen

Grace Mann

Thomas G Braga

Brant Clayton Boren

Lisa Esther Dalrymple

Hiroyuki Tsuruoka

Ila Sircar

Kristjan S Gudmundsson

Ronald Larry Hoppe

Tsuyoshi Homma

William C Stevens

Anthony Olivier

Vincent Denosta

Francis Novak

Bassam B Damaj

Wei Xu

Michael M Morrissey

Derek Redmore

Noriyuki Hayashi

Volodimir Slobodyanyuk

Sunder Ramachandran

Vladimir Jovancicevic

Donald Hutson

Keiji Saito

Grahame Nigel Taylor

Vasu Jammalamadaka

Ellen K Kick

Harold L Becker

Ping Huang

Zhengwei Liu

Benjamin Pratt

Jackaline Dalgard Julien

Nadia Haq

Michael L Walker

Gene F Brock

Peter Ordentlich

Eddie C French

James A Dougherty

William S Tait

Yusuke Asoh

Tracey Jackson

Haiying Zhang

Jackline Eve Dalgard

Sarah Hudson

Shao-Po Lu

Dora V Galvan

Jeff Chen

Benjie T Outlaw

Thane D Schaffer

Thame D Schaffer

James B Dobbs

Peter E Brown

John P Mullen

Evelyn W Purdy

Richard A Rodgers

Stephen R Keenan

Jonathan Collins

Rose Tompkins

Xiao Hui Gu

Tie Lin Wang

Masatoshi Honzumi

William Stevens

Jeffery Dean Kahl

Systems and methods are disclosed herein for processing one or more document and/or hierarchal project. For example, a system is disclosed having memory storing the document as a data file comprising content data. The system also includes at least one processor coupled to the at least one memory and configured to designate a portion of the content data as micro content; receive user input providing a phrase; and generate a phrase map configured to associate the phrase with the designated micro content and store the phrase map as phrase map data, the phrase map data comprising at least the phrase associated with a reference indicative of the associated micro content.

Methods and systems for creating and managing micro content from an electronic document

Systems and methods are disclosed herein for disclosed for controlling the display of content in web-based documents based on a characteristic of a viewport used to render that content. For example, a method comprising storing a document as a data file comprising content data and storing control data as one or more control data files; applying tags to a portion of the content data according to user input; designating media query rules for each of the tags, each media query rule responsive to one or more viewport characteristics; and generating control data based, in part, on said designation, the control data comprising each of tags in association with the respectively designated media queries rules, wherein, when the output file is rendered, the at least a portion of the content data is displayed responsive to the media query rules corresponding thereto based on the tags.

Generating responsive content from an electronic document

In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin Ecompound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Methods and compositions for treating Raynaud's disease

Corrosion to a metal surface in contact with corrosion forming components within an aqueous-based fluid system may be decreased, prevented, and/or inhibited by contacting the metal surface(s) with apatite forming components and forming at least one apatite species on the surface with the apatite forming components. The apatite forming components may be or include phosphates, organophosphates and combinations thereof. In a non-limiting embodiment, the apatite forming components may further include fluorides, chlorides, calcium, and combinations thereof.

Decreasing corrosion on metal surfaces with apatite forming components

Solid-state electronic light detection and ranging (LIDAR) is disclosed. In one aspect, an electronic device for use in a LIDAR system is provided. The electronic device includes a plurality of electrically controllable light-direction-changing elements. The electronic device is configured to receive, from a laser, a beam of light. The electronic device also receives, from a controller, a series of signals that control the electrically controllable light-direction-changing elements to generate a successive series of different diffraction grating patterns configured to move at least one intensity maxima to a corresponding successive series of locations across a field of view (FOV).

Solid-state electronic light detection and ranging (LIDAR)

Methods and compositions for treating raynaud's disease

Aldehydes useful as HS sulfide scavengers may be corrosive to some metals such as steel, iron and aluminum, but the corrosive effect of the aldehydes may be mitigated by employing a corrosion inhibitor selected from the group consisting of a di-basic soluble phosphate salt, a tri-basic soluble phosphate salt, a phosphate ester, a thiophosphate ester, a thioamine, a Mannich Reaction Product, and combinations thereof.

Inhibiting corrosion caused by aqueous aldehyde solutions

Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.

Imidazole based LXR modulators

Compositions containing a small molecule therapeutic and an alkyl N,N-disubstituted amino acetate are disclosed. Inclusion of the alkyl N,N-disubstituted amino acetate enhances the pharmacokinetic properties of the small molecule therapeutic.

Compositions of small molecule therapeutics

In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions.

Antimicrobial compounds and methods of use

The present invention comprises TGR5 agonists of structural formula I, wherein X, R, R, and Rare defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity

Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

Quinazolinone modulators of nuclear receptors

Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

Modulators of LXR

Growing community of inventors

San Diego, CA, United States of America

Richard Martin